Q8NI17 (IL31R_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Names and origin

Protein names

Recommended name:
Interleukin-31 receptor subunit alpha
Short name=IL-31 receptor subunit alpha
Short name=IL-31R subunit alpha
Short name=IL-31R-alpha
Short name=IL-31RA

Alternative name(s):
Cytokine receptor-like 3
GLM-R
Short name=hGLM-R
Gp130-like monocyte receptor
Short name=Gp130-like receptor
ZcytoR17

Gene names

Name:	IL31RA
Synonyms:	CRL3, GPL
ORF Names:	UNQ6368/PRO21073/PRO21384

Organism

Homo sapiens (Human) [Reference proteome]

Taxonomic identifier

9606 [NCBI]

Taxonomic lineage

cellular organisms › Eukaryota › Opisthokonta › Metazoa › Eumetazoa › Bilateria › Deuterostomia › Chordata › Craniata › Vertebrata › Gnathostomata › Teleostomi › Euteleostomi › Sarcopterygii › Tetrapoda › Amniota › Mammalia › Theria › Eutheria › Euarchontoglires › Primates › Haplorrhini › Simiiformes › Catarrhini › Hominoidea › Hominidae › Homininae › Homo

Protein attributes

Sequence length	732 AA.
Sequence status	Complete.
Sequence processing	The displayed sequence is further processed into a mature form.
Protein existence	Evidence at protein level

General annotation (Comments)

Function	Associates with OSMR to form the interleukin-31 receptor which activates STAT3 and to a lower extent STAT1 and STAT5. May function in skin immunity. Ref.1 Ref.2 Ref.8 Ref.9 Ref.10
Subunit structure	Heterodimer with OSMR. Interacts with JAK1 and STAT3. Ref.2 Ref.10
Subcellular location	Cell membrane; Single-pass type I membrane protein Probable.
Tissue specificity	Expressed at low levels in testis, ovary, brain, prostate, placenta, thymus, bone marrow, trachea and skin. Detected in all of the myelomonocytic lineage. Expressed in CD14- and CD56-positive blood cells and by macrophages (at protein level). Ref.1 Ref.2 Ref.8 Ref.11
Induction	Up-regulated in lesional keratinocytes of patients with atopic dermatitis. Up-regulated by IFNG/IFN-gamma and bacterial lipopolysaccharides (LPS). Ref.1 Ref.2 Ref.8 Ref.11
Post-translational modification	N-glycosylated. Ref.8
Involvement in disease	Amyloidosis, primary localized cutaneous, 2 (PLCA2) [MIM:613955]: A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins. Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.12
Sequence similarities	Belongs to the type I cytokine receptor family. Type 2 subfamily. Contains 5 fibronectin type-III domains.
Sequence caution	The sequence AAS86444.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended. The sequence AAS86445.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally extended.

Ontologies

Keywords
Biological process	Immunity
Cellular component	Cell membrane Membrane
Coding sequence diversity	Alternative splicing Polymorphism
Disease	Amyloidosis Disease mutation
Domain	Repeat Signal Transmembrane Transmembrane helix
Molecular function	Receptor
PTM	Glycoprotein
Technical term	Complete proteome Direct protein sequencing Reference proteome
Gene Ontology (GO)
Biological_process	JAK-STAT cascade Inferred from expression pattern Ref.1. Source: UniProtKB MAPK cascade Non-traceable author statement Ref.1. Source: UniProtKB defense response Non-traceable author statement Ref.1. Source: UniProtKB homeostatic process Non-traceable author statement Ref.1. Source: UniProtKB macrophage differentiation Non-traceable author statement Ref.1. Source: UniProtKB monocyte differentiation Inferred from expression pattern Ref.1. Source: UniProtKB negative regulation of apoptotic process Non-traceable author statement Ref.1. Source: UniProtKB negative regulation of macrophage activation Non-traceable author statement Ref.1. Source: UniProtKB positive regulation of cell proliferation Inferred from direct assay Ref.1. Source: UniProtKB positive regulation of transcription, DNA-dependent Non-traceable author statement Ref.1. Source: UniProtKB positive regulation of tyrosine phosphorylation of Stat3 protein Inferred from expression pattern Ref.1. Source: UniProtKB positive regulation of tyrosine phosphorylation of Stat5 protein Inferred from expression pattern Ref.1. Source: UniProtKB transmembrane receptor protein tyrosine kinase signaling pathway Non-traceable author statement Ref.1. Source: UniProtKB
Cellular_component	integral to membrane Non-traceable author statement Ref.1. Source: UniProtKB plasma membrane Inferred from electronic annotation. Source: UniProtKB-SubCell
Molecular_function	cytokine binding Non-traceable author statement Ref.1. Source: UniProtKB cytokine receptor activity Traceable author statement Ref.1. Source: UniProtKB protein kinase binding Non-traceable author statement Ref.1. Source: UniProtKB transcription coactivator activity Non-traceable author statement Ref.1. Source: UniProtKB
Complete GO annotation...

Alternative products

This entry describes 12 isoforms produced by alternative splicing. [Align] [Select]

Isoform 1 (identifier: Q8NI17-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.

Isoform 2 (identifier: Q8NI17-2)

Also known as: v3;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MCIRQLKFFTTACVCECPQNILSPQPSCVNLGM

Isoform 3 (identifier: Q8NI17-3)

Also known as: v4;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM
     639-649: YVTCPFRPDCP → TRILSSCPTSI
     650-732: Missing.

Isoform 4 (identifier: Q8NI17-4)

Also known as: v2;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MCIRQLKFFTTACVCECPQNILSPQPSCVNLGM
     325-732: Missing.

Isoform 5 (identifier: Q8NI17-5)

Also known as: v1;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MCIRQLKFFTTACVCECPQNILSPQPSCVNLGM
     639-649: YVTCPFRPDCP → TRILSSCPTSI
     650-732: Missing.

Isoform 6 (identifier: Q8NI17-6)

The sequence of this isoform differs from the canonical sequence as follows:
     1-110: Missing.

Note: No experimental confirmation available.

Isoform 7 (identifier: Q8NI17-7)

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM
     464-469: GGKGFS → A
     498-501: TSAG → YSGG
     502-732: Missing.

Note: No experimental confirmation available.

Isoform 8 (identifier: Q8NI17-8)

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MCIRQLKFFTTACVCECPQNILSPQPSCVNLGM
     469-550: SKTVNSSILQ...YGLKKPNKLT → CKHAHSEVEK...RVLRKWKELL
     551-732: Missing.

Note: No experimental confirmation available.

Isoform 9 (identifier: Q8NI17-9)

Also known as: GPL560; short;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM
     548-732: Missing.

Note: Major isoform. Dominant negative IL31 receptor.

Isoform 10 (identifier: Q8NI17-10)

Also known as: GPL610;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM
     593-598: LKPCST → RARYQA
     599-732: Missing.

Isoform 11 (identifier: Q8NI17-11)

Also known as: GPL626;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM
     593-613: LKPCSTPSDKLVIDKLVVNFG → KGSELGTKLKFKPLISLDCAF
     614-732: Missing.

Isoform 12 (identifier: Q8NI17-12)

Also known as: GPL745; long;

The sequence of this isoform differs from the canonical sequence as follows:
     1-1: M → MKLSPQPSCVNLGM

Note: Major isoform. Functional IL31 receptor.

Sequence annotation (Features)

	Feature key	Position(s)	Length	Description	Graphical view	Feature identifier
Molecule processing
	Signal peptide	1 – 19	19	Ref.7
	Chain	20 – 732	713	Interleukin-31 receptor subunit alpha		PRO_0000274572
Regions
	Topological domain	20 – 519	500	Extracellular Potential
	Transmembrane	520 – 540	21	Helical; Potential
	Topological domain	541 – 732	192	Cytoplasmic Potential
	Domain	22 – 116	95	Fibronectin type-III 1
	Domain	121 – 222	102	Fibronectin type-III 2
	Domain	223 – 315	93	Fibronectin type-III 3
	Domain	319 – 416	98	Fibronectin type-III 4
	Domain	421 – 512	92	Fibronectin type-III 5
Amino acid modifications
	Glycosylation	37	1	N-linked (GlcNAc...) Potential
	Glycosylation	67	1	N-linked (GlcNAc...) Potential
	Glycosylation	93	1	N-linked (GlcNAc...) Potential
	Glycosylation	166	1	N-linked (GlcNAc...) Potential
	Glycosylation	187	1	N-linked (GlcNAc...) Potential
	Glycosylation	277	1	N-linked (GlcNAc...) Potential
	Glycosylation	283	1	N-linked (GlcNAc...) Potential
	Glycosylation	395	1	N-linked (GlcNAc...) Potential
	Glycosylation	455	1	N-linked (GlcNAc...) Potential
	Glycosylation	504	1	N-linked (GlcNAc...) Potential
Natural variations
	Alternative sequence	1 – 110	110	Missing in isoform 6.		VSP_022798
	Alternative sequence	1	1	M → MCIRQLKFFTTACVCECPQN ILSPQPSCVNLGM in isoform 2, isoform 4, isoform 5 and isoform 8.		VSP_022799
	Alternative sequence	1	1	M → MKLSPQPSCVNLGM in isoform 3, isoform 7, isoform 9, isoform 10, isoform 11 and isoform 12.		VSP_022800
	Alternative sequence	325 – 732	408	Missing in isoform 4.		VSP_022801
	Alternative sequence	464 – 469	6	GGKGFS → A in isoform 7.		VSP_022802
	Alternative sequence	469 – 550	82	SKTVN…PNKLT → CKHAHSEVEKNPKPQIDAMD RPVVGMAPPSHCDLQPGMNH LASLNLSENGAKSTHLLGFW GLNESEVTVPERRVLRKWKE LL in isoform 8.		VSP_022803
	Alternative sequence	498 – 501	4	TSAG → YSGG in isoform 7.		VSP_022804
	Alternative sequence	502 – 732	231	Missing in isoform 7.		VSP_022805
	Alternative sequence	548 – 732	185	Missing in isoform 9.		VSP_022806
	Alternative sequence	551 – 732	182	Missing in isoform 8.		VSP_022807
	Alternative sequence	593 – 613	21	LKPCS…VVNFG → KGSELGTKLKFKPLISLDCA F in isoform 11.		VSP_022808
	Alternative sequence	593 – 598	6	LKPCST → RARYQA in isoform 10.		VSP_022809
	Alternative sequence	599 – 732	134	Missing in isoform 10.		VSP_022810
	Alternative sequence	614 – 732	119	Missing in isoform 11.		VSP_022811
	Alternative sequence	639 – 649	11	YVTCPFRPDCP → TRILSSCPTSI in isoform 3 and isoform 5.		VSP_022812
	Alternative sequence	650 – 732	83	Missing in isoform 3 and isoform 5.		VSP_022813
	Natural variant	155	1	D → N. Corresponds to variant rs13184107 [ dbSNP | Ensembl ].		VAR_030328
	Natural variant	489	1	S → F in PLCA2. Ref.12		VAR_065809
	Natural variant	497	1	S → N. Corresponds to variant rs161704 [ dbSNP | Ensembl ].		VAR_030329
Experimental info
	Mutagenesis	639	1	Y → A: No effect on STAT1 and STAT3 activation. Slight decrease; when associated with A-670 and A-708. Ref.9 Ref.10
	Mutagenesis	639	1	Y → F: Abrogates STAT5 activation. Mild effect on STAT1 activation. No effect on STAT3 activation. Ref.9 Ref.10
	Mutagenesis	670	1	Y → A: No effect on STAT1 and STAT3 activation. Slight decrease; when associated with A-639 and A-708. Ref.9 Ref.10
	Mutagenesis	670	1	Y → F: No effect on STAT3 and STAT5 activation. Mild effect on STAT1 activation. Ref.9 Ref.10
	Mutagenesis	708	1	Y → A: No effect on STAT1 and STAT3 activation. Slight decrease; when associated with A-639 and A-670. Ref.9 Ref.10
	Mutagenesis	708	1	Y → F: Abrogates STAT3 activation. Loss of interaction with STAT3. Mild effect on STAT1 activation. No effect on STAT5 activation. Ref.9 Ref.10

Sequences

	Sequence		Length	Mass (Da)
	Isoform 1 [UniParc]. Last modified October 1, 2002. Version 1. Checksum: 30F84BD3DD99A20E	FASTA	732	82,954
	10 20 30 40 50 60 MMWTWALWML PSLCKFSLAA LPAKPENISC VYYYRKNLTC TWSPGKETSY TQYTVKRTYA 70 80 90 100 110 120 FGEKHDNCTT NSSTSENRAS CSFFLPRITI PDNYTIEVEA ENGDGVIKSH MTYWRLENIA 130 140 150 160 170 180 KTEPPKIFRV KPVLGIKRMI QIEWIKPELA PVSSDLKYTL RFRTVNSTSW MEVNFAKNRK 190 200 210 220 230 240 DKNQTYNLTG LQPFTEYVIA LRCAVKESKF WSDWSQEKMG MTEEEAPCGL ELWRVLKPAE 250 260 270 280 290 300 ADGRRPVRLL WKKARGAPVL EKTLGYNIWY YPESNTNLTE TMNTTNQQLE LHLGGESFWV 310 320 330 340 350 360 SMISYNSLGK SPVATLRIPA IQEKSFQCIE VMQACVAEDQ LVVKWQSSAL DVNTWMIEWF 370 380 390 400 410 420 PDVDSEPTTL SWESVSQATN WTIQQDKLKP FWCYNISVYP MLHDKVGEPY SIQAYAKEGV 430 440 450 460 470 480 PSEGPETKVE NIGVKTVTIT WKEIPKSERK GIICNYTIFY QAEGGKGFSK TVNSSILQYG 490 500 510 520 530 540 LESLKRKTSY IVQVMASTSA GGTNGTSINF KTLSFSVFEI ILITSLIGGG LLILIILTVA 550 560 570 580 590 600 YGLKKPNKLT HLCWPTVPNP AESSIATWHG DDFKDKLNLK ESDDSVNTED RILKPCSTPS 610 620 630 640 650 660 DKLVIDKLVV NFGNVLQEIF TDEARTGQEN NLGGEKNGYV TCPFRPDCPL GKSFEELPVS 670 680 690 700 710 720 PEIPPRKSQY LRSRMPEGTR PEAKEQLLFS GQSLVPDHLC EEGAPNPYLK NSVTAREFLV 730 SEKLPEHTKG EV
	Isoform 2 (v3) [UniParc]. Checksum: DC1D6BB2EA6AF15F	FASTA	764	86,481
	10 20 30 40 50 60 MCIRQLKFFT TACVCECPQN ILSPQPSCVN LGMMWTWALW MLPSLCKFSL AALPAKPENI 70 80 90 100 110 120 SCVYYYRKNL TCTWSPGKET SYTQYTVKRT YAFGEKHDNC TTNSSTSENR ASCSFFLPRI 130 140 150 160 170 180 TIPDNYTIEV EAENGDGVIK SHMTYWRLEN IAKTEPPKIF RVKPVLGIKR MIQIEWIKPE 190 200 210 220 230 240 LAPVSSDLKY TLRFRTVNST SWMEVNFAKN RKDKNQTYNL TGLQPFTEYV IALRCAVKES 250 260 270 280 290 300 KFWSDWSQEK MGMTEEEAPC GLELWRVLKP AEADGRRPVR LLWKKARGAP VLEKTLGYNI 310 320 330 340 350 360 WYYPESNTNL TETMNTTNQQ LELHLGGESF WVSMISYNSL GKSPVATLRI PAIQEKSFQC 370 380 390 400 410 420 IEVMQACVAE DQLVVKWQSS ALDVNTWMIE WFPDVDSEPT TLSWESVSQA TNWTIQQDKL 430 440 450 460 470 480 KPFWCYNISV YPMLHDKVGE PYSIQAYAKE GVPSEGPETK VENIGVKTVT ITWKEIPKSE 490 500 510 520 530 540 RKGIICNYTI FYQAEGGKGF SKTVNSSILQ YGLESLKRKT SYIVQVMAST SAGGTNGTSI 550 560 570 580 590 600 NFKTLSFSVF EIILITSLIG GGLLILIILT VAYGLKKPNK LTHLCWPTVP NPAESSIATW 610 620 630 640 650 660 HGDDFKDKLN LKESDDSVNT EDRILKPCST PSDKLVIDKL VVNFGNVLQE IFTDEARTGQ 670 680 690 700 710 720 ENNLGGEKNG YVTCPFRPDC PLGKSFEELP VSPEIPPRKS QYLRSRMPEG TRPEAKEQLL 730 740 750 760 FSGQSLVPDH LCEEGAPNPY LKNSVTAREF LVSEKLPEHT KGEV
	Isoform 3 (v4) [UniParc]. Checksum: A49F6363C4B33582	FASTA	662	74,876
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEGGKG 490 500 510 520 530 540 FSKTVNSSIL QYGLESLKRK TSYIVQVMAS TSAGGTNGTS INFKTLSFSV FEIILITSLI 550 560 570 580 590 600 GGGLLILIIL TVAYGLKKPN KLTHLCWPTV PNPAESSIAT WHGDDFKDKL NLKESDDSVN 610 620 630 640 650 660 TEDRILKPCS TPSDKLVIDK LVVNFGNVLQ EIFTDEARTG QENNLGGEKN GTRILSSCPT SI
	Isoform 4 (v2) [UniParc]. Checksum: BF4DAD24F5048E1D	FASTA	356	41,026
	10 20 30 40 50 60 MCIRQLKFFT TACVCECPQN ILSPQPSCVN LGMMWTWALW MLPSLCKFSL AALPAKPENI 70 80 90 100 110 120 SCVYYYRKNL TCTWSPGKET SYTQYTVKRT YAFGEKHDNC TTNSSTSENR ASCSFFLPRI 130 140 150 160 170 180 TIPDNYTIEV EAENGDGVIK SHMTYWRLEN IAKTEPPKIF RVKPVLGIKR MIQIEWIKPE 190 200 210 220 230 240 LAPVSSDLKY TLRFRTVNST SWMEVNFAKN RKDKNQTYNL TGLQPFTEYV IALRCAVKES 250 260 270 280 290 300 KFWSDWSQEK MGMTEEEAPC GLELWRVLKP AEADGRRPVR LLWKKARGAP VLEKTLGYNI 310 320 330 340 350 WYYPESNTNL TETMNTTNQQ LELHLGGESF WVSMISYNSL GKSPVATLRI PAIQEK
	Isoform 5 (v1) [UniParc]. Checksum: C69CC4EF9AC55E42	FASTA	681	77,047
	10 20 30 40 50 60 MCIRQLKFFT TACVCECPQN ILSPQPSCVN LGMMWTWALW MLPSLCKFSL AALPAKPENI 70 80 90 100 110 120 SCVYYYRKNL TCTWSPGKET SYTQYTVKRT YAFGEKHDNC TTNSSTSENR ASCSFFLPRI 130 140 150 160 170 180 TIPDNYTIEV EAENGDGVIK SHMTYWRLEN IAKTEPPKIF RVKPVLGIKR MIQIEWIKPE 190 200 210 220 230 240 LAPVSSDLKY TLRFRTVNST SWMEVNFAKN RKDKNQTYNL TGLQPFTEYV IALRCAVKES 250 260 270 280 290 300 KFWSDWSQEK MGMTEEEAPC GLELWRVLKP AEADGRRPVR LLWKKARGAP VLEKTLGYNI 310 320 330 340 350 360 WYYPESNTNL TETMNTTNQQ LELHLGGESF WVSMISYNSL GKSPVATLRI PAIQEKSFQC 370 380 390 400 410 420 IEVMQACVAE DQLVVKWQSS ALDVNTWMIE WFPDVDSEPT TLSWESVSQA TNWTIQQDKL 430 440 450 460 470 480 KPFWCYNISV YPMLHDKVGE PYSIQAYAKE GVPSEGPETK VENIGVKTVT ITWKEIPKSE 490 500 510 520 530 540 RKGIICNYTI FYQAEGGKGF SKTVNSSILQ YGLESLKRKT SYIVQVMAST SAGGTNGTSI 550 560 570 580 590 600 NFKTLSFSVF EIILITSLIG GGLLILIILT VAYGLKKPNK LTHLCWPTVP NPAESSIATW 610 620 630 640 650 660 HGDDFKDKLN LKESDDSVNT EDRILKPCST PSDKLVIDKL VVNFGNVLQE IFTDEARTGQ 670 680 ENNLGGEKNG TRILSSCPTS I
	Isoform 6 [UniParc]. Checksum: 80E4A3592D040EC6	FASTA	622	70,363
	10 20 30 40 50 60 MTYWRLENIA KTEPPKIFRV KPVLGIKRMI QIEWIKPELA PVSSDLKYTL RFRTVNSTSW 70 80 90 100 110 120 MEVNFAKNRK DKNQTYNLTG LQPFTEYVIA LRCAVKESKF WSDWSQEKMG MTEEEAPCGL 130 140 150 160 170 180 ELWRVLKPAE ADGRRPVRLL WKKARGAPVL EKTLGYNIWY YPESNTNLTE TMNTTNQQLE 190 200 210 220 230 240 LHLGGESFWV SMISYNSLGK SPVATLRIPA IQEKSFQCIE VMQACVAEDQ LVVKWQSSAL 250 260 270 280 290 300 DVNTWMIEWF PDVDSEPTTL SWESVSQATN WTIQQDKLKP FWCYNISVYP MLHDKVGEPY 310 320 330 340 350 360 SIQAYAKEGV PSEGPETKVE NIGVKTVTIT WKEIPKSERK GIICNYTIFY QAEGGKGFSK 370 380 390 400 410 420 TVNSSILQYG LESLKRKTSY IVQVMASTSA GGTNGTSINF KTLSFSVFEI ILITSLIGGG 430 440 450 460 470 480 LLILIILTVA YGLKKPNKLT HLCWPTVPNP AESSIATWHG DDFKDKLNLK ESDDSVNTED 490 500 510 520 530 540 RILKPCSTPS DKLVIDKLVV NFGNVLQEIF TDEARTGQEN NLGGEKNGYV TCPFRPDCPL 550 560 570 580 590 600 GKSFEELPVS PEIPPRKSQY LRSRMPEGTR PEAKEQLLFS GQSLVPDHLC EEGAPNPYLK 610 620 NSVTAREFLV SEKLPEHTKG EV
	Isoform 7 [UniParc]. Checksum: 5DC85C59E170D44B	FASTA	509	58,390
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEAKTV 490 500 NSSILQYGLE SLKRKTSYIV QVMASYSGG
	Isoform 8 [UniParc]. Checksum: 5EC7B07B84B36057	FASTA	582	66,605
	10 20 30 40 50 60 MCIRQLKFFT TACVCECPQN ILSPQPSCVN LGMMWTWALW MLPSLCKFSL AALPAKPENI 70 80 90 100 110 120 SCVYYYRKNL TCTWSPGKET SYTQYTVKRT YAFGEKHDNC TTNSSTSENR ASCSFFLPRI 130 140 150 160 170 180 TIPDNYTIEV EAENGDGVIK SHMTYWRLEN IAKTEPPKIF RVKPVLGIKR MIQIEWIKPE 190 200 210 220 230 240 LAPVSSDLKY TLRFRTVNST SWMEVNFAKN RKDKNQTYNL TGLQPFTEYV IALRCAVKES 250 260 270 280 290 300 KFWSDWSQEK MGMTEEEAPC GLELWRVLKP AEADGRRPVR LLWKKARGAP VLEKTLGYNI 310 320 330 340 350 360 WYYPESNTNL TETMNTTNQQ LELHLGGESF WVSMISYNSL GKSPVATLRI PAIQEKSFQC 370 380 390 400 410 420 IEVMQACVAE DQLVVKWQSS ALDVNTWMIE WFPDVDSEPT TLSWESVSQA TNWTIQQDKL 430 440 450 460 470 480 KPFWCYNISV YPMLHDKVGE PYSIQAYAKE GVPSEGPETK VENIGVKTVT ITWKEIPKSE 490 500 510 520 530 540 RKGIICNYTI FYQAEGGKGF CKHAHSEVEK NPKPQIDAMD RPVVGMAPPS HCDLQPGMNH 550 560 570 580 LASLNLSENG AKSTHLLGFW GLNESEVTVP ERRVLRKWKE LL
	Isoform 9 (GPL560) (short) [UniParc]. Checksum: BDE67D9F753AED29	FASTA	560	63,638
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEGGKG 490 500 510 520 530 540 FSKTVNSSIL QYGLESLKRK TSYIVQVMAS TSAGGTNGTS INFKTLSFSV FEIILITSLI 550 560 GGGLLILIIL TVAYGLKKPN
	Isoform 10 (GPL610) [UniParc]. Checksum: EE437BBA84162525	FASTA	611	69,491
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEGGKG 490 500 510 520 530 540 FSKTVNSSIL QYGLESLKRK TSYIVQVMAS TSAGGTNGTS INFKTLSFSV FEIILITSLI 550 560 570 580 590 600 GGGLLILIIL TVAYGLKKPN KLTHLCWPTV PNPAESSIAT WHGDDFKDKL NLKESDDSVN 610 TEDRIRARYQ A
	Isoform 11 (GPL626) [UniParc]. Checksum: FA80DED660647A2F	FASTA	626	71,023
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEGGKG 490 500 510 520 530 540 FSKTVNSSIL QYGLESLKRK TSYIVQVMAS TSAGGTNGTS INFKTLSFSV FEIILITSLI 550 560 570 580 590 600 GGGLLILIIL TVAYGLKKPN KLTHLCWPTV PNPAESSIAT WHGDDFKDKL NLKESDDSVN 610 620 TEDRIKGSEL GTKLKFKPLI SLDCAF
	Isoform 12 (GPL745) (long) [UniParc]. Checksum: C4A17642CCC0549B	FASTA	745	84,309
	10 20 30 40 50 60 MKLSPQPSCV NLGMMWTWAL WMLPSLCKFS LAALPAKPEN ISCVYYYRKN LTCTWSPGKE 70 80 90 100 110 120 TSYTQYTVKR TYAFGEKHDN CTTNSSTSEN RASCSFFLPR ITIPDNYTIE VEAENGDGVI 130 140 150 160 170 180 KSHMTYWRLE NIAKTEPPKI FRVKPVLGIK RMIQIEWIKP ELAPVSSDLK YTLRFRTVNS 190 200 210 220 230 240 TSWMEVNFAK NRKDKNQTYN LTGLQPFTEY VIALRCAVKE SKFWSDWSQE KMGMTEEEAP 250 260 270 280 290 300 CGLELWRVLK PAEADGRRPV RLLWKKARGA PVLEKTLGYN IWYYPESNTN LTETMNTTNQ 310 320 330 340 350 360 QLELHLGGES FWVSMISYNS LGKSPVATLR IPAIQEKSFQ CIEVMQACVA EDQLVVKWQS 370 380 390 400 410 420 SALDVNTWMI EWFPDVDSEP TTLSWESVSQ ATNWTIQQDK LKPFWCYNIS VYPMLHDKVG 430 440 450 460 470 480 EPYSIQAYAK EGVPSEGPET KVENIGVKTV TITWKEIPKS ERKGIICNYT IFYQAEGGKG 490 500 510 520 530 540 FSKTVNSSIL QYGLESLKRK TSYIVQVMAS TSAGGTNGTS INFKTLSFSV FEIILITSLI 550 560 570 580 590 600 GGGLLILIIL TVAYGLKKPN KLTHLCWPTV PNPAESSIAT WHGDDFKDKL NLKESDDSVN 610 620 630 640 650 660 TEDRILKPCS TPSDKLVIDK LVVNFGNVLQ EIFTDEARTG QENNLGGEKN GYVTCPFRPD 670 680 690 700 710 720 CPLGKSFEEL PVSPEIPPRK SQYLRSRMPE GTRPEAKEQL LFSGQSLVPD HLCEEGAPNP 730 740 YLKNSVTARE FLVSEKLPEH TKGEV

References

	« Hide 'large scale' referencesShow 'large scale' references »
[1]	"A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5." Ghilardi N., Li J., Hongo J.-A., Yi S., Gurney A., De Sauvage F.J. J. Biol. Chem. 277:16831-16836(2002) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, INDUCTION.
[2]	"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice." Dillon S.R., Sprecher C., Hammond A., Bilsborough J., Rosenfeld-Franklin M., Presnell S.R., Haugen H.S., Maurer M., Harder B., Johnston J., Bort S., Mudri S., Kuijper J.L., Bukowski T., Shea P., Dong D.L., Dasovich M., Grant F.J. , Lockwood L., Levin S.D., LeCiel C., Waggie K., Day H., Topouzis S., Kramer J., Kuestner R., Chen Z., Foster D., Parrish-Novak J., Gross J.A. Nat. Immunol. 5:752-760(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 5), FUNCTION, OLIGOMERIZATION, TISSUE SPECIFICITY, INDUCTION.
[3]	"A novel soluble type 1 cytokine receptor." Zhang W., Wan T., He L., Yuan Z., Cao X. Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
[4]	"The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment." Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E. , Heldens S., Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M. Genome Res. 13:2265-2270(2003) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 8).
[5]	"The DNA sequence and comparative analysis of human chromosome 5." Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S., Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M., She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S. , Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M., Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M. Nature 431:268-274(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[6]	"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
[7]	"Signal peptide prediction based on analysis of experimentally verified cleavage sites." Zhang Z., Henzel W.J. Protein Sci. 13:2819-2824(2004) [PubMed] [Europe PMC] [Abstract] Cited for: PROTEIN SEQUENCE OF 20-34.
[8]	"GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor." Diveu C., Lelievre E., Perret D., Lagrue Lak-Hal A.-H., Froger J., Guillet C., Chevalier S., Rousseau F., Wesa A., Preisser L., Chabbert M., Gauchat J.-F., Galy A., Gascan H., Morel A. J. Biol. Chem. 278:49850-49859(2003) [PubMed] [Europe PMC] [Abstract] Cited for: ALTERNATIVE SPLICING (ISOFORMS 9; 10; 11 AND 12), FUNCTION, TISSUE SPECIFICITY, INDUCTION, GLYCOSYLATION.
[9]	"Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling." Diveu C., Lagrue Lak-Hal A.-H., Froger J., Ravon E., Grimaud L., Barbier F., Hermann J., Gascan H., Chevalier S. Eur. Cytokine Netw. 15:291-302(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, MUTAGENESIS OF TYR-639; TYR-670 AND TYR-708.
[10]	"Characterization of the signaling capacities of the novel gp130-like cytokine receptor." Dreuw A., Radtke S., Pflanz S., Lippok B.E., Heinrich P.C., Hermanns H.M. J. Biol. Chem. 279:36112-36120(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, INTERACTION WITH JAK1 AND STAT3, MUTAGENESIS OF TYR-639; TYR-670 AND TYR-708.
[11]	"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis." Bilsborough J., Leung D.Y.M., Maurer M., Howell M., Boguniewicz M., Yao L., Storey H., LeCiel C., Harder B., Gross J.A. J. Allergy Clin. Immunol. 117:418-425(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INDUCTION, TISSUE SPECIFICITY.
[12]	"Novel IL31RA gene mutation and ancestral OSMR mutant allele in familial primary cutaneous amyloidosis." Lin M.W., Lee D.D., Liu T.T., Lin Y.F., Chen S.Y., Huang C.C., Weng H.Y., Liu Y.F., Tanaka A., Arita K., Lai-Cheong J., Palisson F., Chang Y.T., Wong C.K., Matsuura I., McGrath J.A., Tsai S.F. Eur. J. Hum. Genet. 18:26-32(2010) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT PLCA2 PHE-489.
+	Additional computationally mapped references.

Cross-references

Sequence databases
EMBL GenBank DDBJ	AF486620 mRNA. Translation: AAM27958.1. AY499339 mRNA. Translation: AAS86444.1. Different initiation. AY499340 mRNA. Translation: AAS86445.1. Different initiation. AY499341 mRNA. Translation: AAS86446.1. AY499342 mRNA. Translation: AAS86447.1. AF106913 mRNA. Translation: AAL36452.1. AY358117 mRNA. Translation: AAQ88484.1. AY358740 mRNA. Translation: AAQ89100.1. AC008914 Genomic DNA. No translation available. BC110490 mRNA. Translation: AAI10491.1.
IPI	IPI00465082. IPI00478188. IPI00827493. IPI00827666. IPI00827821. IPI00827852. IPI00827904. IPI00827945. IPI00827997. IPI00828071. IPI00828090. IPI00828127.
RefSeq	NP_001229565.1. NM_001242636.1. NP_001229566.1. NM_001242637.1. NP_001229567.1. NM_001242638.1. NP_001229568.1. NM_001242639.1. NP_620586.3. NM_139017.5.
UniGene	Hs.55378.
3D structure databases
HSSP	HSSP built from PDB template 1BQU based on UniProtKB P40189.
ProteinModelPortal	Q8NI17.
ModBase	Search...
PTM databases
PhosphoSite	Q8NI17.
Polymorphism databases
DMDM	74730327.
Proteomic databases
PaxDb	Q8NI17.
PRIDE	Q8NI17.
Protocols and materials databases
StructuralBiologyKnowledgebase	Search...
Genome annotation databases
Ensembl	ENST00000354961; ENSP00000347047; ENSG00000164509. ENST00000359040; ENSP00000351935; ENSG00000164509. ENST00000396834; ENSP00000380046; ENSG00000164509. ENST00000396836; ENSP00000380048; ENSG00000164509. ENST00000447346; ENSP00000415900; ENSG00000164509. ENST00000490985; ENSP00000427533; ENSG00000164509.
GeneID	133396.
KEGG	hsa:133396.
UCSC	uc003jqk.3. human. uc003jql.3. human. uc003jqm.3. human. uc003jqn.3. human. uc003jqo.3. human. uc021xyq.1. human.
Organism-specific databases
CTD	133396.
GeneCards	GC05P055185.
HGNC	HGNC:18969. IL31RA.
MIM	609510. gene. 613955. phenotype.
neXtProt	NX_Q8NI17.
Orphanet	49804. Lichen amyloidosis.
PharmGKB	PA134952624.
GenAtlas	Search...
Phylogenomic databases
eggNOG	NOG72763.
HOVERGEN	HBG081788.
InParanoid	Q8NI17.
OMA	DTWMVEW.
Gene expression databases
Bgee	Q8NI17.
Genevestigator	Q8NI17.
Family and domain databases
Gene3D	2.60.40.10. 3 hits.
InterPro	IPR003961. Fibronectin_type3. IPR013783. Ig-like_fold. IPR015321. IL6_recept-bd. [Graphical view]
Pfam	PF00041. fn3. 2 hits. PF09240. IL6Ra-bind. 1 hit. [Graphical view]
SMART	SM00060. FN3. 4 hits. [Graphical view]
SUPFAM	SSF49265. FN_III-like. 4 hits.
PROSITE	PS50853. FN3. 5 hits. [Graphical view]
ProtoNet	Search...
Other
ChiTaRS	IL31RA. human.
GenomeRNAi	133396.
NextBio	83210.
SOURCE	Search...

Entry information

Entry name

IL31R_HUMAN

Accession

Primary (citable) accession number: Q8NI17
Secondary accession number(s): A6NIF8 , Q2TBA1, Q6EBC3, Q6EBC4, Q6EBC5, Q6EBC6, Q6UWL8, Q8WYJ0

Entry history

Integrated into UniProtKB/Swiss-Prot:	February 6, 2007
Last sequence update:	October 1, 2002
Last modified:	May 1, 2013
This is version 93 of the entry and version 1 of the sequence. [Complete history]

Entry status

Reviewed (UniProtKB/Swiss-Prot)

Annotation program

Chordata Protein Annotation Program

Disclaimer

Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.